#South Korea #Seoul #XPOVIO #Multiple Myeloma #Antengene

XPOVIO® Secures Reimbursement Approval for Second Indication in South Korea

On March 1, 2026, Antengene Corporation Limited announced a significant milestone in cancer treatment. The National Health Insurance Service (NHIS) of South Korea granted reimbursement approval for XPOVIO® (selinexor), marking it as the first XPO1 inhibitor to receive such endorsement for adult patients diagnosed with multiple myeloma (MM) following one prior therapy. This approval is crucial for enhancing healthcare access and aligning with the pressing needs in the oncology sector.

Expanding Horizons for XPOVIO®

XPOVIO® had previously been recognized for its efficacy and safety in South Korea, receiving approvals for three indications covering multiple myeloma and diffuse large B-cell lymphoma (DLBCL). With the latest addition, two of these indications can now be reimbursed, enhancing treatment accessibility.

This approval paves the way for XPOVIO® in combination with bortezomib and dexamethasone, targeting patients who have undergone at least one cancer treatment before. It offers a new hope for those battling relapsed or refractory forms of the disease, which can be particularly challenging to manage.

Enhancing Patient Access and Care

Antengene's commitment to improving healthcare continues as it expands its reach across the Asia Pacific region. By receiving reimbursement approval, the company aims to provide broader access to its innovative therapies for patients suffering from hematological malignancies in South Korea. Previously, XPOVIO® was reimbursed for patients with relapsed or refractory multiple myeloma who had undergone four or more previous therapies. The expanded reimbursement scheme is poised to significantly benefit more individuals, thereby contributing to improved management of multiple myeloma.

Revolutionary Mechanism of Action

XPOVIO® is notable for being the world's first orally available selective XPO1 inhibitor. Its unique mechanism of action offers a promising alternative in the landscape of cancer treatment, characterized by its innovative approach to tackling hematological malignancies. Besides South Korea, XPOVIO® has gained approvals in ten other countries across the Asia Pacific region, with national insurance coverage already established in five markets, including Australia and Singapore.

As Antengene forges ahead, it remains steadfast in its mission to facilitate the accessibility of advanced treatments for patients across varying markets. Continuous efforts to further insurance coverage indicate a dedicated approach to prioritizing patient care in oncology.

About Antengene

Founded in Shanghai, Antengene Corporation Limited operates as a leading global biotech entity striving to develop groundbreaking therapeutics targeting significant unmet medical needs in areas such as autoimmune diseases, solid tumors, and hematological malignancies. The company has a balanced pipeline, from preclinical projects to commercial-phase assets, including several proprietary therapies and innovative platforms like AnTenGager™, which enables targeted T cell engagement in oncology applications.

In conclusion, the reimbursement approval for XPOVIO® marks a pivotal stride in cancer care for multiple myeloma patients in South Korea. It reflects Antengene's relentless dedication to advancing therapeutic options and ensuring that effective treatments reach those in need, enhancing the quality of healthcare in the region.